uploads///medic _

AstraZeneca’s Lynparza Continues to Dominate

By

Jun. 17 2019, Published 12:27 p.m. ET

Lynparza’s growth trends

In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan. On July 27, 2017, AstraZeneca and Merck entered into a collaboration to codevelop and co-commercialize Lynparza. Lynparza reported a net profit of $79 million for Merck & Co. (MRK) in the first quarter.

Article continues below advertisement

On December 19, AstraZeneca issued a press release announcing the FDA’s approval of Lynparza in a first-line maintenance setting for BRCA-mutated advanced ovarian cancer. On April 10, the company issued a press release announcing the European Commission’s approval of Lynparza in germline BRCA-mutated metastatic breast cancer indications. Label expansions across multiple markets are expected to drive the drug’s sales in future quarters.

Performance by markets

According to its first-quarter earnings investor presentation, Lynparza reported revenue of $119 million in the US market in the first quarter, a YoY rise of over 80% driven by leadership in first-line and second-line ovarian cancer maintenance settings and a robust launch in germline BRCA-mutated breast cancer indications. In Europe, the drug reported sales of $65 million, a YoY rise of over 62% driven by increasing diagnosis rates, rising market penetration in terms of commercial launches and reimbursement in the second-line ovarian cancer maintenance setting, and drug supply for clinical trials. The drug reported sales of $27 million in established markets in the rest of the world, $22 million of which came from Japan. The drug also reported $26 million in revenue in emerging markets.

Lynparza in pancreatic cancer indications

On February 26, AstraZeneca issued a press release announcing positive results from its Phase 3 POLO trial evaluating Lynparza as a first-line maintenance therapy in the treatment of germline BRCA-mutated pancreatic cancer. On June 2, the company issued a press release announcing additional favorable results from its POLO trial that were presented at the 2019 American Society of Clinical Oncology meeting. The company expects to file a regulatory application for Lynparza in this indication in the second half of 2019.

Advertisement

More From Market Realist